Enterotrophic Effects of Glucagon-Like Peptide 2 Are Enhanced by Neurotensin

David A. Litvak, B. Mark Evers, Mark Hellmich, Courtney Townsend

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Combination therapy with enterotrophic agents may be useful in patients with the short bowel syndrome. The gut hormones neurotensin (NT) and glucagon-like peptide 2 (GLP-2) are potent enterotrophic factors when administered alone; however, their combined effects are not known. Using a GLP-2-producing tumor (STC-1), we determined whether administration of NT enhances the effect of GLP-2 on intestinal growth. Athymic mice were injected with STC-1 cells (6 × 106) subcutaneously. Twenty-three days after STC-1 implantation, mice received either NT (300 μg/kg or 600 μg/kg) or saline solution (control) subcutaneously three times a day for 6 days. Two groups of tumor-free mice received either saline or NT for 6 days. At sacrifice, jejunum and ileum were collected, weighed, and analysed for DNA and protein content. In the jejunum, NT combined with GLP-2 (from STC-1) increased weight, protein content (markers of mucosal hypertrophy), and DNA content (a marker of mucosal hyperplasia), compared to either NT or GLP-2 alone. In the ileum, the combination of NT and GLP-2 significantly increased weight and/or protein content compared to NT or GLP-2 alone. Administration of NT enhances the enterotrophic effects of GLP-2, augmenting hypertrophy of the entire small bowel and hyperplasia of the jejunum. The combination of NT and GLP-2 may be useful to enhance intestinal growth in patients with the short bowel syndrome.

Original languageEnglish (US)
Pages (from-to)432-440
Number of pages9
JournalJournal of Gastrointestinal Surgery
Volume3
Issue number4
StatePublished - Jul 1999

Fingerprint

Glucagon-Like Peptide 2
Neurotensin
Jejunum
Short Bowel Syndrome
Ileum
Hypertrophy
Hyperplasia
Weights and Measures
Proteins
DNA
Growth
Nude Mice
Sodium Chloride
Neoplasms

Keywords

  • Glucagon-like peptide 2
  • Intestinal growth factors
  • Neurotensin
  • Short bowel syndrome

ASJC Scopus subject areas

  • Surgery

Cite this

Enterotrophic Effects of Glucagon-Like Peptide 2 Are Enhanced by Neurotensin. / Litvak, David A.; Evers, B. Mark; Hellmich, Mark; Townsend, Courtney.

In: Journal of Gastrointestinal Surgery, Vol. 3, No. 4, 07.1999, p. 432-440.

Research output: Contribution to journalArticle

@article{7974c6d18ebe410d90d24e5ea3141b35,
title = "Enterotrophic Effects of Glucagon-Like Peptide 2 Are Enhanced by Neurotensin",
abstract = "Combination therapy with enterotrophic agents may be useful in patients with the short bowel syndrome. The gut hormones neurotensin (NT) and glucagon-like peptide 2 (GLP-2) are potent enterotrophic factors when administered alone; however, their combined effects are not known. Using a GLP-2-producing tumor (STC-1), we determined whether administration of NT enhances the effect of GLP-2 on intestinal growth. Athymic mice were injected with STC-1 cells (6 × 106) subcutaneously. Twenty-three days after STC-1 implantation, mice received either NT (300 μg/kg or 600 μg/kg) or saline solution (control) subcutaneously three times a day for 6 days. Two groups of tumor-free mice received either saline or NT for 6 days. At sacrifice, jejunum and ileum were collected, weighed, and analysed for DNA and protein content. In the jejunum, NT combined with GLP-2 (from STC-1) increased weight, protein content (markers of mucosal hypertrophy), and DNA content (a marker of mucosal hyperplasia), compared to either NT or GLP-2 alone. In the ileum, the combination of NT and GLP-2 significantly increased weight and/or protein content compared to NT or GLP-2 alone. Administration of NT enhances the enterotrophic effects of GLP-2, augmenting hypertrophy of the entire small bowel and hyperplasia of the jejunum. The combination of NT and GLP-2 may be useful to enhance intestinal growth in patients with the short bowel syndrome.",
keywords = "Glucagon-like peptide 2, Intestinal growth factors, Neurotensin, Short bowel syndrome",
author = "Litvak, {David A.} and Evers, {B. Mark} and Mark Hellmich and Courtney Townsend",
year = "1999",
month = "7",
language = "English (US)",
volume = "3",
pages = "432--440",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Enterotrophic Effects of Glucagon-Like Peptide 2 Are Enhanced by Neurotensin

AU - Litvak, David A.

AU - Evers, B. Mark

AU - Hellmich, Mark

AU - Townsend, Courtney

PY - 1999/7

Y1 - 1999/7

N2 - Combination therapy with enterotrophic agents may be useful in patients with the short bowel syndrome. The gut hormones neurotensin (NT) and glucagon-like peptide 2 (GLP-2) are potent enterotrophic factors when administered alone; however, their combined effects are not known. Using a GLP-2-producing tumor (STC-1), we determined whether administration of NT enhances the effect of GLP-2 on intestinal growth. Athymic mice were injected with STC-1 cells (6 × 106) subcutaneously. Twenty-three days after STC-1 implantation, mice received either NT (300 μg/kg or 600 μg/kg) or saline solution (control) subcutaneously three times a day for 6 days. Two groups of tumor-free mice received either saline or NT for 6 days. At sacrifice, jejunum and ileum were collected, weighed, and analysed for DNA and protein content. In the jejunum, NT combined with GLP-2 (from STC-1) increased weight, protein content (markers of mucosal hypertrophy), and DNA content (a marker of mucosal hyperplasia), compared to either NT or GLP-2 alone. In the ileum, the combination of NT and GLP-2 significantly increased weight and/or protein content compared to NT or GLP-2 alone. Administration of NT enhances the enterotrophic effects of GLP-2, augmenting hypertrophy of the entire small bowel and hyperplasia of the jejunum. The combination of NT and GLP-2 may be useful to enhance intestinal growth in patients with the short bowel syndrome.

AB - Combination therapy with enterotrophic agents may be useful in patients with the short bowel syndrome. The gut hormones neurotensin (NT) and glucagon-like peptide 2 (GLP-2) are potent enterotrophic factors when administered alone; however, their combined effects are not known. Using a GLP-2-producing tumor (STC-1), we determined whether administration of NT enhances the effect of GLP-2 on intestinal growth. Athymic mice were injected with STC-1 cells (6 × 106) subcutaneously. Twenty-three days after STC-1 implantation, mice received either NT (300 μg/kg or 600 μg/kg) or saline solution (control) subcutaneously three times a day for 6 days. Two groups of tumor-free mice received either saline or NT for 6 days. At sacrifice, jejunum and ileum were collected, weighed, and analysed for DNA and protein content. In the jejunum, NT combined with GLP-2 (from STC-1) increased weight, protein content (markers of mucosal hypertrophy), and DNA content (a marker of mucosal hyperplasia), compared to either NT or GLP-2 alone. In the ileum, the combination of NT and GLP-2 significantly increased weight and/or protein content compared to NT or GLP-2 alone. Administration of NT enhances the enterotrophic effects of GLP-2, augmenting hypertrophy of the entire small bowel and hyperplasia of the jejunum. The combination of NT and GLP-2 may be useful to enhance intestinal growth in patients with the short bowel syndrome.

KW - Glucagon-like peptide 2

KW - Intestinal growth factors

KW - Neurotensin

KW - Short bowel syndrome

UR - http://www.scopus.com/inward/record.url?scp=0033155712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033155712&partnerID=8YFLogxK

M3 - Article

C2 - 10482697

AN - SCOPUS:0033155712

VL - 3

SP - 432

EP - 440

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 4

ER -